接受抗纤维化治疗的IPF患者死亡原因与肌少症研究
本研究纳入接受抗纤维化治疗(AFT)的IPF患者队列,并与未接受AFT的历史队列及对照比较死亡原因,通过CT测量竖脊肌横截面积(ESMCSA)和面积衰减指数(ESMMA)评估肌少症。结果显示AFT患者骨骼肌丢失但体重无明显下降,最常见死因为慢性呼吸衰竭(约60%),低ESMCSA为独立不良预后因素。
要点
- 接受AFT的IPF患者存在骨骼肌丢失但BMI与对照相似,提示体重正常者仍需评估肌少症。
- AFT患者最常见死因为慢性呼吸衰竭,约占60%,肺癌死亡比例下降。
- 低ESMCSA是独立不良预后因素,联合ESMCSA、%FVC预计值和BMI可清晰区分预后。
核心结论
- 接受AFT的IPF患者存在无明显体重下降的骨骼肌丢失,主要死于慢性呼吸衰竭,骨骼肌消耗具有预后意义。
研究设计与样本
- 研究包含接受AFT的IPF患者两个队列、未接受AFT的IPF历史队列及对照。
- 死亡原因与历史队列比较,肌少症通过CT测量ESMCSA和ESMMA评估。
主要发现
- IPF患者ESMCSA更小、ESMMA更低,但BMI与对照相似。
- 接受AFT患者最常见死因为慢性呼吸衰竭,约占60%,肺癌死亡比例下降。
- 低ESMCSA为与较差生存率相关的独立预后因素。
- 联合ESMCSA、%FVC预计值和BMI可提供清晰的预后区分。
关键数值与推荐
- 慢性呼吸衰竭占接受AFT患者死亡原因约60%。
- 低ESMCSA为独立预后因素,联合ESMCSA、%FVC预计值和BMI可区分预后。
临床怎么用
- 对接受AFT的IPF患者应关注肌少症评估,即使体重无明显下降。
- 可利用CT测量的ESMCSA联合%FVC预计值和BMI进行预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Recent research has highlighted the fundamental role of sarcopenia, characterized by loss of skeletal muscle mass and strength, with a risk of poor outcomes. AFT preserves lung function by preventing the annual decline in FVC and is associated with improved outcomes in patients with IPF. However, altered cause of death and prognostic implications of sarcopenia in patients with IPF receiving AFT remain unknown. METHODS: This study comprised two cohorts of patients with IPF receiving AFT, historical cohort of IPF patients without AFT and controls. The cause of mortality was compared with a historical cohort. Sarcopenia was assessed by measuring the ESMCSA and ESMMA via CT. RESULTS: Patients with IPF had smaller ESMCSA and lower ESMMA but similar BMI than controls, suggesting patients with IPF had skeletal muscle loss without any obvious body weight loss. The most common cause of mortality in patients receiving AFT was chronic respiratory failure, accounting for approximately 60%, and decreased proportions of LC were found. Subsequently, low ESMCSA was an independent prognostic factor associated with worse survival rates. Furthermore, combined assessment of ESMCSA , %FVC predicted and BMI values provided clear prognostic distinction. CONCLUSION: Patients with IPF receiving AFT showed skeletal muscle loss without obvious weight loss. These patients mostly died by chronic respiratory failure, and skeletal muscle wasting has prognostic significance, suggesting that preventing sarcopenia as well as preserving lung function are important for managing these patients.
引用
- Suzuki Y, Aono Y, Kono M, et al. Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy. Respirology. 2020. PMID: 32969124. doi:10.1111/resp.13943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。